АКТУАЛЬНЫЕ ВОПРОСЫ ТЕРАПИИ ОСТЕОАРТРОЗА В РЕАЛЬНОЙ КЛИНИЧЕСКОЙ ПРАКТИКЕ

Л. К. Пешехонова; Д. В. Пешехонов; П. А. Красюков

doi:10.21518/2079-701X-2017-0-97-102

АКТУАЛЬНЫЕ ВОПРОСЫ ТЕРАПИИ ОСТЕОАРТРОЗА В РЕАЛЬНОЙ КЛИНИЧЕСКОЙ ПРАКТИКЕ

Л. К. Пешехонова, Д. В. Пешехонов, П. А. Красюков

https://doi.org/10.21518/2079-701X-2017-0-97-102

Полный текст:

PDF (Rus)

Аннотация

Статья посвящена вопросам лечения остеоартроза – одного из самых распространенных заболеваний опорно-двигательного аппарата, вызывающего болевой синдром, снижение качества жизни, ограничение социальной активности и нетрудоспособность. Приводятся данные об эффективности оригинального препарата кристаллического глюкозамина сульфата (ДОНА).

Ключевые слова

остеоартроз, болевой синдром, симптоммодифицирующие препараты замедленного действия, кристаллический глюкозамина сульфат

Об авторах

Л. К. Пешехонова

Дорожная клиническая больница на ст. Воронеж-1 ОАО «РЖД»; Воронежский государственный медицинский университет им. Н.Н. Бурденко Минздрава России
Россия

д.м.н.

Д. В. Пешехонов

Дорожная клиническая больница на ст. Воронеж-1 ОАО «РЖД»; Воронежский государственный медицинский университет им. Н.Н. Бурденко Минздрава России
Россия
д.м.н.

П. А. Красюков

Дорожная клиническая больница на ст. Воронеж-1 ОАО «РЖД»; Воронежский государственный медицинский университет им. Н.Н. Бурденко Минздрава России
Россия
к.м.н.

Список литературы

1. Алексеева Л.И. Остеоартроз: проблема века. Медицинский совет, 2013, 5: 78-80.

2. Кашеварова Н.Г., Зайцева Е.М., Пушкова О.В., Смирнов А.В., Алексеева Л.И. Факторы прогрессирования остеоартроза коленных суставов (5-летнее проспективное наблюдение). Остеопороз и остеопатии, 2013, 2: 9-11.

3. Насонова В.А., Цветкова Е.С. Фармакотерапия остеоартроза. Лечащий врач, 2004, 7: 22-24.

4. Чичасова Н.В. Проблема боли при остеоартрозе. Лечащий врач, 2007, 2: 31-34.

5. Altman RD Glucosamine therapy for knee osteoarthritis: pharmacokinetic considerations. Expert Rev Clin Pharmacol, 2009 Jul, 2(4): 359-71.

6. Bijlsma JW, Berenbaum F, Lafeber FP. Osteoarthritis: an update with relevance for clinical practice. Lancet, 2011 Jun 18, 377(9783): 2115-26.

7. Bruyère O, Cooper C, Pelletier JP, Branco J, Luisa Brandi M, Guillemin F, Hochberg MC, Kanis JA, Kvien TK, Martel-Pelletier J, Rizzoli R, Silverman S, Reginster JY. An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: a report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Semin Arthritis Rheum, 2014 Dec, 44(3): 253-63.

8. Bruyere O, Pavelka K, Rovati LC, Deroisy R, Olejarova M, Gatterova J, Giacovelli G, Reginster JY. Glucosamine sulfate reduces osteoarthritis progression in postmenopausal women with knee osteoarthritis: evidence from two 3-year studies. Menopause, 2004 Mar-Apr, 11(2): 138-43.

9. Bruyere O, Pavelka K, Rovati LC, Gatterová J, Giacovelli G, Olejarová M, Deroisy R, Reginster JY. Total joint replacement after glucosamine sulphate treatment in knee osteoarthritis: results of a mean 8-year observation of patients from two previous 3-year, randomised, placebo-controlled trials. Osteoarthritis Cartilage, 2008 Feb, 16(2): 254-60.

10. Chiusaroli R, Piepoli T, Zanelli T, Ballanti P, Lanza M, Rovati LC, Caselli G Experimental Pharmacology of Glucosamine Sulfate. Int J Rheumatol, 2011, 2011: 939265.

11. Eriksen P, Bartels EM, Altman RD, Bliddal H, Juhl C, Christensen R. Risk of bias and brand explain the observed inconsistency in trials on glucosamine for symptomatic relief of osteoarthritis: a meta-analysis of placebo-controlled trials. Arthritis Care Res (Hoboken), 2014 Dec, 66(12): 1844-55.

12. European Medicines Agency CPMP/EWP/784/97 Rev. 1. Guideline on clinical investigation of medicinal products used in the treatment of osteoarthritis. January 2010.

13. Giordano N, Fioravanti A, Panagiotas P, Montella A, Giorgi G, Nuti R The efficacy and tolerability of glucosamine sulfate in the treatment of knee osteoarthritis: A randomized, double-blind, placebo-controlled trial. Current Therapeutic Research, 2009 Jun, 70(3): 185-096.

14. Henrotin Y, Mobasheri A, Marty M. Is there any scientific evidence for the use of glucosamine in the management of human osteoarthritis? Arthritis Res Ther, 2012 Jan 30, 14(1): 201.

15. Hochberg MC, Altman RD, April KT, Benkhalti M, Guyatt G, McGowan J, Towheed T, Welch V, Wells G, Tugwell P; American College of Rheumato-logy American College of Rheumatology 2012 recommendations for the use of nonpharmaco-logic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken), 2012 Apr, 64(4): 465-74.

16. Jordan KM, Arden NK, Doherty M, Bannwarth B, Bijlsma JW, Dieppe P, Gunther K, Hauselmann H, Herrero-Beaumont G, Kaklamanis P, Lohmander S, Leeb B, Lequesne M, Mazieres B, Martin-Mola E, Pavelka K, Pendleton A, Punzi L, Serni U, Swoboda B, Verbruggen G, Zimmerman-Gorska I, Dougados M; Standing Committee for International Clinical Studies Including Therapeutic Trials ESCISIT EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis, 2003 Dec, 62(12): 1145-55.

17. Lane NE, Brandt K, Hawker G, Peeva E, Schreyer E, Tsuji W, Hochberg MC OARSI-FDA initiative: defining the disease state of osteoarthritis. Osteoarthritis Cartilage, 2011 May, 19(5): 478-82.

18. Mazzuca SA, Brandt KD, Katz BP, Hanna MP, Melfi CA. Reduced utilization and cost of primary care clinic visits resulting from self-care education for patients with osteoarthritis of the knee. Arthritis Rheum, 1999, 42: 1267-73.

19. McAlindon TE, Bannuru RR, Sullivan MC, Arden NK, Berenbaum F, Bierma-Zeinstra SM, Hawker GA, Henrotin Y, Hunter DJ, Kawaguchi H, Kwoh K, Lohmander S, Rannou F, Roos EM, Underwood M OARSI guidelines for the nonsurgical management of knee osteoarthritis. Osteoarthritis Cartilage, 2014 Mar, 22(3): 363-88.

20. Müller-Fassbender H, Bach GL, Haase W, Rovati LC, Setnikar I. Glucosamine sulfate compared to ibuprofen in osteoarthritis of the knee. Osteoarthritis Cartilage, 1994 Mar, 2(1): 61-9.

21. National Clinical Guideline Centre Osteoarthritis: Care and Management in Adults. Clinical Guideline CG177, 2014.

22. Neogi T, Nevvit M, Niu J et al. Subchondral bone attrition may be a reflection of compartment-specific mechanical load: the MOST Study. Ann. Rheum. Dis., 2010, 69(5): 841-4.

23. Bruyère O, Cooper C, Pelletier JP, Maheu E, Rannou F, Branco J, Luisa Brandi M, Kanis JA, Altman RD, Hochberg MC, Martel-Pelletier J, Reginster JY. A consensus statement on the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) algorithm for the management of knee osteoarthritis-From evidence-based medicine to the real-life setting. Semin Arthritis Rheum, 2016 Feb, 45(4 Suppl): S3-11.

24. Pereira D, Peleteiro B, Araújo J, Branco J, Santos RA, Ramos E. The effect of osteoarthritis definition on prevalence and incidence estimates: a systematic review. Osteoarthritis Cartilage, 2011 Nov, 19(11): 1270-85.

25. Reginster JY, Deroisy R, Rovati LC, Lee RL, Lejeune E, Bruyere O, Giacovelli G, Henrotin Y, Dacre JE, Gossett C. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet, 2001 Jan 27, 357(9252): 251-6.

26. Reginster JY, Neuprez A, Lecart MP, Sarlet N, Bruyere O. Role of glucosamine in the treatment for osteoarthritis. Rheumatol Int, 2012 Oct, 32(10): 2959-67.

27. Roman-Blas JA, Castañeda S, Largo R, Herrero-Beaumont G. Glucosamine sulfate for knee osteoarthritis: science and evidence-based use. Therapy, 2010 Nov, 7(6): 591-604. DOI: http:// dx.doi.org/10.2217/thy.10.67.

28. Rovati LC Crystalline glucosamine sulfate in the only SYSADOA that decreases consumption of NSAIDs in knee osteoarthritis: results from the PEGASus cohort. Oral presentation; 2014 OARSI World Congress on Osteoarthritis, Paris, France, 24-27 April 2014.

29. Rovati LC, Girolami F, Persiani S. Crystalline glucosamine sulfate in the management of knee osteoarthritis: efficacy, safety, and pharmacokinetic properties. Ther Adv Musculoskelet Dis, 2012 Jun, 4(3): 167-80.

30. Simon RR, Marks V, Leeds AR, Anderson JW. A comprehensive review of oral glucosamine use and effects on glucose metabolism in normal and diabetic individuals. Diabetes Metab Res Rev, 2011 Jan, 27(1): 14-27.

31. Stumpf JL, Lin SW. Effect of glucosamine on glucose control. Ann Pharmacother, 2006 Apr, 40(4): 694-8.

32. Uitterlinden EJ, Jahr H, Koevoet JL, Jenniskens YM, Bierma-Zeinstra SM, Degroot J, Verhaar JA, Weinans H, van Osch GJ. Glucosamine decreases expression of anabolic and catabolic genes in human osteoarthritic cartilage explants. Osteoarthritis Cartilage, 2006 Mar, 14(3): 250-7.

33. Vaz A. Double-blind clinical evaluation of the relative efficacy of ibuprofen and glucosamine sulphate in the management of osteoarthrosis of the knee in out-patients. Curr Med Res, 1982, 8: 145-9.

34. Zhang W, Nuki G, Moskowitz RW, Abramson S, Altman RD, Arden NK, Bierma-Zeinstra S, Brandt KD, Croft P, Doherty M, Dougados M, Hochberg M, Hunter DJ, Kwoh K, Lohmander LS, Tugwell P OARSI recommendations for the management of hip and knee osteoarthritis: part III: Changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis Cartilage, 2010 Apr, 18(4): 476-99.

Для цитирования:

Пешехонова Л.К., Пешехонов Д.В., Красюков П.А. АКТУАЛЬНЫЕ ВОПРОСЫ ТЕРАПИИ ОСТЕОАРТРОЗА В РЕАЛЬНОЙ КЛИНИЧЕСКОЙ ПРАКТИКЕ. Медицинский Совет. 2017;(1S):97-102. https://doi.org/10.21518/2079-701X-2017-0-97-102

For citation:

Poshekhonova L.K., Poshekhonov D.V., Krasyukov P.A. TOPICAL ISSUES OF OSTEOARTHRITIS TREATMENT IN CLINICAL PRACTICE. Medical Council. 2017;(1S):97-102. (In Russ.) https://doi.org/10.21518/2079-701X-2017-0-97-102